AKT1S1
From Wikipedia, the free encyclopedia
AKT1 substrate 1 (proline-rich)
|
|||||||||||
Identifiers | |||||||||||
Symbol(s) | AKT1S1; Lobe; MGC2865; PRAS40 | ||||||||||
External IDs | OMIM: 610221 MGI: 1914855 HomoloGene: 12162 | ||||||||||
|
|||||||||||
RNA expression pattern | |||||||||||
Orthologs | |||||||||||
Human | Mouse | ||||||||||
Entrez | 84335 | 67605 | |||||||||
Ensembl | ENSG00000204673 | ENSMUSG00000011096 | |||||||||
Uniprot | Q96B36 | Q9D1F4 | |||||||||
Refseq | NM_032375 (mRNA) NP_115751 (protein) |
NM_026270 (mRNA) NP_080546 (protein) |
|||||||||
Location | Chr 19: 55.06 - 55.07 Mb | Chr 7: 44.72 - 44.72 Mb | |||||||||
Pubmed search | [1] | [2] |
AKT1 substrate 1 (proline-rich), also known as AKT1S1, is a human gene.[1]
[edit] References
[edit] Further reading
- Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.". Gene 138 (1-2): 171–4. PMID 8125298.
- Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library.". Gene 200 (1-2): 149–56. PMID 9373149.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi: . PMID 12477932.
- Kovacina KS, Park GY, Bae SS, et al. (2003). "Identification of a proline-rich Akt substrate as a 14-3-3 binding partner.". J. Biol. Chem. 278 (12): 10189–94. doi: . PMID 12524439.
- Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs.". Nat. Genet. 36 (1): 40–5. doi: . PMID 14702039.
- Saito A, Narasimhan P, Hayashi T, et al. (2004). "Neuroprotective role of a proline-rich Akt substrate in apoptotic neuronal cell death after stroke: relationships with nerve growth factor.". J. Neurosci. 24 (7): 1584–93. doi: . PMID 14973226.
- Beausoleil SA, Jedrychowski M, Schwartz D, et al. (2004). "Large-scale characterization of HeLa cell nuclear phosphoproteins.". Proc. Natl. Acad. Sci. U.S.A. 101 (33): 12130–5. doi: . PMID 15302935.
- Jin J, Smith FD, Stark C, et al. (2004). "Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization.". Curr. Biol. 14 (16): 1436–50. doi: . PMID 15324660.
- Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).". Genome Res. 14 (10B): 2121–7. doi: . PMID 15489334.
- Huang B, Porter G (2006). "Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis.". Acta Pharmacol. Sin. 26 (10): 1253–8. PMID 16174443.
- Kimura K, Wakamatsu A, Suzuki Y, et al. (2006). "Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.". Genome Res. 16 (1): 55–65. doi: . PMID 16344560.
- Olsen JV, Blagoev B, Gnad F, et al. (2006). "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.". Cell 127 (3): 635–48. doi: . PMID 17081983.
- Vander Haar E, Lee SI, Bandhakavi S, et al. (2007). "Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40.". Nat. Cell Biol. 9 (3): 316–23. doi: . PMID 17277771.
- Sancak Y, Thoreen CC, Peterson TR, et al. (2007). "PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase.". Mol. Cell 25 (6): 903–15. doi: . PMID 17386266.
- Wang L, Harris TE, Roth RA, Lawrence JC (2007). "PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding.". J. Biol. Chem. 282 (27): 20036–44. doi: . PMID 17510057.
- Fonseca BD, Smith EM, Lee VH, et al. (2007). "PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex.". J. Biol. Chem. 282 (34): 24514–24. doi: . PMID 17604271.